Literature DB >> 22366274

Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.

Andrew H Evans1, Michael J Farrell, Stephen J Gibson, Robert D Helme, Shen-Yang Lim.   

Abstract

BACKGROUND: Motor response complications that arise with repeated L-dopa administration for the treatment of Parkinson's disease are well understood but the relationship between motor response complications and affect are not. We proposed that patients with dyskinesias would report rebound worsening in affect during wearing-off of L-dopa effect.
METHODS: Fifty Parkinson's disease patients with were assessed with the Purdue Pegboard test and rated Positive Affect and Negative Affect after overnight withdrawal of dopaminergic medications and half hourly for 6 h after a standard L-dopa challenge. Patients were carefully classified into stable responder (n = 12), fluctuator (n = 15), and dyskinetic (n = 23) groups.
RESULTS: Positive Affect was improved by L-dopa in dyskinetics and to a lesser degree in fluctuators but not in stable responders. At T = 4-6 h, Positive Affect rebounded below baseline in dyskinetics only. On regression analysis, rebound worsening positively correlated with ratings of dyskinesia severity. Negative Affect improved with L-dopa in all groups and tended to remain below baseline for 6 h after L-dopa challenge. Peak effects of L-dopa on Positive Affect and Negative Affect occurred significantly earlier than effects on Purdue Pegboard test and were positively correlated with L-dopa equivalent daily dose.
CONCLUSION: There is a clinical dissociation between L-dopa effects on motor function, Positive Affect and Negative Affect. Rebound worsening in Positive Affect occurred only in dyskinetic patients and the onset of rebound worsening occurred before the end of the motor benefit phase. These observations could explain why some Parkinson patients report wearing-off symptoms despite the external impression of good motor control.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366274     DOI: 10.1016/j.parkreldis.2012.01.020

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

Review 1.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

2.  Limb-kinetic apraxia affects activities of daily living in Parkinson's disease: a multi-center study.

Authors:  T Foki; T Vanbellingen; C Lungu; W Pirker; S Bohlhalter; T Nyffeler; J Kraemmer; D Haubenberger; F Ph S Fischmeister; E Auff; M Hallett; R Beisteiner
Journal:  Eur J Neurol       Date:  2016-05-01       Impact factor: 6.089

3.  Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease.

Authors:  Will Lee; Andrew H Evans; David R Williams
Journal:  Mov Disord Clin Pract       Date:  2017-05-25

4.  A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  Andrew H Evans; Jade Kettlewell; Sarah McGregor; Katya Kotschet; Robert I Griffiths; Malcolm Horne
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

5.  Objective measurement in routine care of people with Parkinson's disease improves outcomes.

Authors:  Parisa Farzanehfar; Holly Woodrow; Michelle Braybrook; Sarah McGregor; Andrew Evans; Frank Nicklason; Malcolm Horne
Journal:  NPJ Parkinsons Dis       Date:  2018-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.